Live
FierceBiotechCity aims to lay foundation for RNAi renaissance with nearly $100M series BEndpoints News#ADA26: AstraZeneca GLP-1 pill cuts weight 10.5% after six monthsRoche MediaRoche and Nurix Therapeutics Announce Global Collaboration | PharmExec - Pharmaceutical ExecutiveBioPharma DiveCity banks nearly $100M for next-gen RNAi drugsEndpoints NewsIncyte CEO sees $2B Vega deal aiding a post-Jakafi futureClinical OMICsCortical On/Off Switch Provides Sleep Benefits to Awake MiceClinical OMICsGLP-1 Drugs Linked to Lower Rates of Substance Use DisordersEndpoints NewsCity Therapeutics gets $99M to gather data on three RNAi medicinesClinical OMICsProPure™ Endotoxin-Free Proteins for Reliable Cancer ResearchClinical OMICsTARGA Imager Enables High-Resolution Imaging of Neurodevelopmental ModelsBioPharma DiveRoche stakes $700M on Nurix’s protein-degrading drugClinical OMICsSignatera™ as a Pan-Cancer Decision-Making Tool to Illuminate the Care Pathway
BioWorld Apr 24, 2026

Pharma industry faces long haul to get return on investment from AI

Pharma industry faces long haul to get return on investment from AI

Original
Body unavailable. Use the original source.